SCHEMBL14349716

SCHEMBL14349716

CC(CC(=O)Nc1ccccc1C(=O)O)c1ccc2c(F)c(O)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 11/20 0.49
▸ KDM4E B2RXH2 3/20 0.46
▸ RECQL P46063 1/20 0.46
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP8 Q96LD8 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42
▸ SENP6 Q9GZR1 1/20 0.42
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C8 P10632 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ PTGER4 P35408 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ CDC25B P30305 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14349718 0.84 KDM4E (0.51) HCAR2KDM4ERECQLKMT2AMEN1
SCHEMBL14349698 0.83 HCAR2 (0.60) HCAR2KDM4ERECQLKMT2AMEN1
SCHEMBL6781577 0.83 KMT2A (0.58) HCAR2KDM4ERECQLKMT2AMEN1
SCHEMBL14349715 0.79 HCAR2 (0.77) HCAR2CYP2C9
SCHEMBL14349697 0.78 HCAR2 (0.64) HCAR2KDM4ERECQLKMT2AMEN1
SCHEMBL14340788 0.76 HCAR2 (0.60) HCAR2KDM4ERECQLKMT2AMEN1
SCHEMBL14349780 0.74 HCAR2 (0.61) HCAR2KDM4ERECQLKMT2AMEN1
SCHEMBL6784915 0.73 KMT2A (0.57) KDM4EKMT2AMEN1CASP3SENP8
SCHEMBL14349899 0.73 KDM4E (0.53) HCAR2KDM4ECASP3CYP2C9LMNA
SCHEMBL14349783 0.73 HCAR2 (0.59) HCAR2KDM4ERECQLKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299101-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2007-12-27 — — US disclosed
US-20070299101-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2007-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299101-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment LDLR, APOB, FFAR1 HCAR2 20/4885KDM4E 4792/4885RECQL 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback